{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:58:14Z","timestamp":1785491894279,"version":"3.56.0"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,31]]},"abstract":"<jats:p>Increased risk of major adverse cardiac events (MACE) may be linked to systemic inflammation for patients with psoriasis. Guselkumab is an effective treatment for psoriasis and psoriatic arthritis that was previously shown to reduce inflammatory biomarkers in three phase 3 randomized controlled trials [to week 16 in VOYAGE 1 (A Study of Guselkumab in the Treatment of Participants with Moderate to Severe Plaque-Type Psoriasis)\/VOYAGE 2 (A Study of Guselkumab in the Treatment of Participants with Moderate to Severe Plaque-Type Psoriasis With Randomised Withdrawal and Retreatment)\u00a0and week 12 in ECLIPSE (A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-Type Psoriasis)\u00a0]. In this post hoc analysis, sustained reduction in neutrophil\/lymphocyte ratio, platelet\/lymphocyte ratio and monocyte\/lymphocyte ratio were observed to week 48 in these three trials for patients who received guselkumab every 8 weeks. This reduction was independent of improvements in Psoriasis Area Severity Index scores. Observational studies are required to identify whether this reduction correlates with a reduction in MACE.<\/jats:p>","DOI":"10.1093\/skinhd\/vzag075","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T11:46:29Z","timestamp":1778240789000},"page":"628-630","source":"Crossref","is-referenced-by-count":0,"title":["Guselkumab treatment of psoriasis results in sustained reduction of systemic inflammatory biomarkers to week 48 in three phase III randomized controlled trials"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6469-3462","authenticated-orcid":false,"given":"Niamh","family":"Kearney","sequence":"first","affiliation":[{"name":"Department of Dermatology, Our Lady of Lourdes Hospital , Drogheda ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"Johnson & Johnson , Zug ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alianu","family":"Akawung","sequence":"additional","affiliation":[{"name":"Johnson & Johnson Research & Development, LLC , Spring House, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kirby","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St Vincent\u2019s University Hospital Dublin , Dublin ,","place":["Ireland"]},{"name":"Charles Institute of Dermatology, University College Dublin , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"2026073105080754400_vzag075-B1","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000062","article-title":"Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"2026073105080754400_vzag075-B2","article-title":"Interleukin-17 links inflammatory cross-talks between comorbid psoriasis and atherosclerosis","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"2026073105080754400_vzag075-B3","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/annrheumdis-2016-209784","article-title":"Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis","volume":"76","author":"Low","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026073105080754400_vzag075-B4","article-title":"Prognostic impact of multiple lymphocyte-based inflammatory indices in acute coronary syndrome patients","volume":"9","author":"Li","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026073105080754400_vzag075-B5","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000545148","article-title":"Treatment of plaque psoriasis with guselkumab reduces systemic inflammatory burden as measured by neutrophil\/lymphocyte ratio, platelet\/lymphocyte ratio, and monocyte\/lymphocyte ratio: a post hoc analysis of three randomised clinical trials","volume":"241","author":"Kearney","year":"2025","journal-title":"Dermatology"},{"key":"2026073105080754400_vzag075-B6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2026073105080754400_vzag075-B7","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2026073105080754400_vzag075-B8","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"2026073105080754400_vzag075-B9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2020.08.032","article-title":"Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): a nested case\u2013control analysis","volume":"84","author":"Langley","year":"2021","journal-title":"J Am Acad Dermatol"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/4\/628\/68527911\/vzag075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/4\/628\/68527911\/vzag075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:08:13Z","timestamp":1785488893000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/6\/4\/628\/8708150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":9,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,6,15]]},"published-print":{"date-parts":[[2026,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/skinhd\/vzag075","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,6,15]]}}}